Assessment by EPISPOT of Circulating Tumor Cells as an Early Predictive Marker of Response to Chemotherapy and Targeted Therapy in Patients With Metastatic Colorectal Cancer in First Line of Treatment
In the aim to study a homogeneous cohort of patients, the investigators will only recruit
patients in first line of treatment and treated by 5-FU (IV), IRINOTECAN et BEVACIZUMAB
Intervention Model: Single Group Assignment, Masking: Open Label
Predictive value of the CTC on the Progression Free Survival
The primary outcome aims to evaluate the predictive value of the early progression of the CTC performed with the EPISPOT assay on the PFS in a cohort of patients treated with 5-FU, IRNOTECAN et AVASTIN (FOLFIRI or XELIRI-AVASTIN) in 1rst line of metastatic colorectal cancer. The progression disease is assessed based on imagery techniques.
Duration study 3 years
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)